Literature DB >> 8324828

Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene.

L D Shultz1, P A Schweitzer, T V Rajan, T Yi, J N Ihle, R J Matthews, M L Thomas, D R Beier.   

Abstract

Mice homozygous for the recessive allelic mutation motheaten (me) or viable motheaten (mev) on chromosome 6 develop severe defects in hematopoiesis. In this paper we present the findings that the me and mev mutations are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. High resolution mapping localized me to an area tightly linked to Hcph on chromosome 6. Abnormalities of the Hcph protein product were demonstrated by Western blot analysis and by activity assays in both me/me and mev/mev mice. Molecular analysis of the Hcph cDNA identified abnormal transcripts in both mutants. DNA sequence analyses of cDNA and genomic clones revealed that both the me and mev mutations are point mutations that result in aberrant splicing of the Hcph transcript. These findings provide the first available animal models for a specific protein-tyrosine phosphatase deficiency, thus facilitating determination of the precise role of this signaling molecule in hematopoiesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324828     DOI: 10.1016/0092-8674(93)90369-2

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  175 in total

1.  CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1.

Authors:  J J Perez-Villar; G S Whitney; M A Bowen; D H Hewgill; A A Aruffo; S B Kanner
Journal:  Mol Cell Biol       Date:  1999-04       Impact factor: 4.272

Review 2.  T cell signal transduction and the role of CD7 in costimulation.

Authors:  R Stillwell; B E Bierer
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

3.  Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter.

Authors:  Q Zhang; P N Raghunath; E Vonderheid; N Odum; M A Wasik
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

4.  ets-2 is a target for an akt (Protein kinase B)/jun N-terminal kinase signaling pathway in macrophages of motheaten-viable mutant mice.

Authors:  J L Smith; A E Schaffner; J K Hofmeister; M Hartman; G Wei; D Forsthoefel; D A Hume; M C Ostrowski
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

5.  Antagonism or synergism. Role of tyrosine phosphatases SHP-1 and SHP-2 in growth factor signaling.

Authors:  Ning Wang; Zhe Li; Ronghua Ding; Gerald D Frank; Takaaki Senbonmatsu; Erwin J Landon; Tadashi Inagami; Zhizhuang Joe Zhao
Journal:  J Biol Chem       Date:  2006-06-08       Impact factor: 5.157

Review 6.  The E3 ubiquitin ligase Itch in T cell activation, differentiation, and tolerance.

Authors:  Yun-Cai Liu
Journal:  Semin Immunol       Date:  2007-04-11       Impact factor: 11.130

7.  Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response.

Authors:  F W Quelle; D Wang; T Nosaka; W E Thierfelder; D Stravopodis; Y Weinstein; J N Ihle
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 8.  The Fas signaling connection between autoimmunity and embryonic lethality.

Authors:  H C Hsu; Y Matsuki; H G Zhang; T Zhou; J D Mountz
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

9.  The Src family kinase, Lyn, suppresses osteoclastogenesis in vitro and in vivo.

Authors:  Hyun-Ju Kim; Kaihua Zhang; Lihong Zhang; F Patrick Ross; Steven L Teitelbaum; Roberta Faccio
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-26       Impact factor: 11.205

Review 10.  SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels.

Authors:  Ulrike Lorenz
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.